These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22388795)

  • 1. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis.
    Jennings BA; Kwok CS; Willis G; Matthews V; Wawruch P; Loke YK
    Pharmacogenet Genomics; 2012 Apr; 22(4):290-304. PubMed ID: 22388795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
    Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
    Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
    Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
    van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
    Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of
    Cevik M; Namal E; Sener ND; Koksal UI; Cagatay P; Deliorman G; Ciftci C; Karaalp A; Susleyici B
    Per Med; 2022 Sep; 19(5):435-444. PubMed ID: 35880438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
    Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
    Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
    Naghibalhossaini F; Shefaghat M; Mansouri A; Jaberi H; Tatar M; Eftekhar E
    Acta Med Iran; 2017 Dec; 55(12):751-758. PubMed ID: 29373881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
    Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
    Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy.
    Zawiah M; Yousef AM; Kadi T; Yousef M; Majdalawi K; Al-Yacoub S; Al-Hiary R; Tantawi D; Mukred R; Ajaj AR
    Drug Metab Pers Ther; 2018 Dec; 33(4):201-205. PubMed ID: 30207288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer.
    Castro-Rojas CA; Esparza-Mota AR; Hernandez-Cabrera F; Romero-Diaz VJ; Gonzalez-Guerrero JF; Maldonado-Garza H; Garcia-Gonzalez IS; Buenaventura-Cisneros S; Sanchez-Lopez JY; Ortiz-Lopez R; Camacho-Morales A; Barboza-Quintana O; Rojas-Martinez A
    Drug Metab Pers Ther; 2017 Dec; 32(4):209-218. PubMed ID: 29257755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population.
    Jang MJ; Kim JW; Jeon YJ; Chong SY; Hong SP; Hwang SG; Oh D; Cho YK; Ji YG; Kim NK
    Gene; 2014 Jan; 533(2):558-64. PubMed ID: 24100087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
    Afzal S; Gusella M; Vainer B; Vogel UB; Andersen JT; Broedbaek K; Petersen M; Jimenez-Solem E; Bertolaso L; Barile C; Padrini R; Pasini F; Jensen SA; Poulsen HE
    Clin Cancer Res; 2011 Jun; 17(11):3822-9. PubMed ID: 21471424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy.
    Jennings BA; Willis G
    Cancer Lett; 2015 Jan; 356(2 Pt A):224-30. PubMed ID: 24614284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer.
    Shitara K; Muro K; Ito S; Sawaki A; Tajika M; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Matsuo K
    Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1311-9. PubMed ID: 20447923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer.
    Yousef AM; Zawiah M; Al-Yacoub S; Kadi T; Tantawi DA; Al-Ramadhani H
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):237-243. PubMed ID: 29845393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Polymorphisms Involved in Folate Metabolism and DNA Methylation with the Risk of Head and Neck Cancer.
    De Castro TB; Rodrigues-Fleming GH; Oliveira-Cucolo JG; Silva JNGD; Silva FP; Raposo LS; Maniglia JV; Pavarino EC; Batista Arantes LMR; Galbiatti-Dias ALS; Maria Goloni Bertollo E
    Asian Pac J Cancer Prev; 2020 Dec; 21(12):3751-3759. PubMed ID: 33369477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
    Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
    J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
    Cohen V; Panet-Raymond V; Sabbaghian N; Morin I; Batist G; Rozen R
    Clin Cancer Res; 2003 May; 9(5):1611-5. PubMed ID: 12738713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.